Disruptive Technology Channel The ARKG ETF Doesn’t Need More Catalysts. It’s Getting Them Anyway By Tom LydonDecember 15, 2020
Disruptive Technology Channel Falling Costs Make Genomics (and Their ETFs) More Attractive than Ever By Tom LydonDecember 9, 2020
Disruptive Technology Channel Up 144% in a Tumultuous 2020? No Surprise for ARKG By Tom LydonDecember 2, 2020
Disruptive Technology Channel How Precision Medicine Will Revolutionize Healthcare By Tom LydonNovember 25, 2020
Disruptive Technology Channel Bad Ideas: The Industries on Innovation’s Chopping Block By Max ChenNovember 17, 2020
Disruptive Technology Channel The Genomics ETF on the Front Lines of Cancer Detection By Tom LydonNovember 16, 2020
Active ETF Channel ARK Genomics Fund Poised for the Future of Healthcare By Tom LydonOctober 26, 2020
Disruptive Technology Channel How CRISPR Future Shapes Up for Hot Genomics ETF By Tom LydonOctober 15, 2020
Disruptive Technology Channel Long Read DNA Sequencing Ready for its Moment. That’s Big for this ETF By Todd ShriberOctober 8, 2020
Thematic Investing Channel Thematic ETF Asset Growth Climbs Even Higher By Todd RosenbluthOctober 7, 2020
Disruptive Technology Channel Another Interesting Week for the Genomics ETF By Todd ShriberSeptember 28, 2020
Disruptive Technology Channel Dark Genes Shine Light on Genomics ETF Opportunity By Tom LydonSeptember 23, 2020
Disruptive Technology Channel Why This Genomics ETF Is a Long-Term Winner By Tom LydonSeptember 15, 2020
Disruptive Technology Channel CRISPR Benefits Available in This Genomics ETF By Tom LydonSeptember 10, 2020
Disruptive Technology Channel Another Exciting Growth Could Lift Long-Term Genomics Outlook By Tom LydonSeptember 3, 2020